Anlon Healthcare Shares Marks Listing on NSE and BSE at Modest Premium of 1%

Anlon Healthcare shares saw a tepid debut on the stock exchanges, with its shares listing at ₹92 on the NSE, just marginally above the IPO issue price of ₹91, indicating a modest premium of approximately 1.10%. On the BSE, Anlon Healthcare shares opened at ₹91, matching its issue price, indicating a flat listing. 

Anlon Healthcare IPO Subscription Details

The ₹121-crore initial public offering (IPO), which ran from August 26 to August 29, was well received by investors, garnering an overall subscription of nearly 7 times. The company raised ₹121.03 crore by offering a fresh issue of 1.33 crore equity shares in a price band of ₹86–91.

Proceeds from the IPO will be utilised for expanding manufacturing capabilities, repaying select borrowings, and funding general corporate requirements.

The IPO was managed by Interactive Financial Services, with KFin Technologies serving as the registrar.

About Anlon Healthcare Limited

Anlon Healthcare specialises in the production of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs). Its offerings span a range of sectors including human pharmaceuticals, nutraceuticals, personal care, and veterinary medicine. Notably, the company is among the limited number of Indian manufacturers of Loxoprofen Sodium Dihydrate, a widely used pain-relief API approved by regulatory bodies in Brazil, Japan, and China.

The company boasts a robust product portfolio, comprising 65 commercialised products, 28 in pilot development, and 49 undergoing validations. It has also ventured into custom manufacturing of complex chemicals, a niche, high-margin segment with significant growth potential.

Also Read: Upcoming IPOs in September 2025: 1 Mainboard and 7 SME IPO Set to Launch till Date

Operational efficiency has shown marked improvement, with capacity utilisation rising sharply to 84% in FY25 from 38% in FY24. Anlon now aims to ramp up its manufacturing capacity from 400 MTPA to 1,100 MTPA to support its growth trajectory.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.